EndoSure, Inc.
StreetZero Signal 62
About EndoSure, Inc.
EndoSure, Inc. is the developer of a non-invasive diagnostic test for endometriosis detection. The company utilizes clinical testing and rapid-result technology to provide half-hour assessments and post-treatment monitoring for physicians and patients. It operates in the diagnostic equipment and medical laboratories sector with a focus on FemTech and HealthTech.
LATEST FUNDINGPrivate Placement
$1.3M
Announced 2026-11-19
TOTAL RAISED$150K
IN THE NEWS
- ๐ EndoSure 2026 Company Profile: Valuation, Funding & Investors | PitchBook
- ๐ EndoSure, Inc.
- ๐ Endosure - 2026 Company Profile, Funding & Competitors - Tracxn
- ๐ EndoSure - Products, Competitors, Financials, Employees, Headquarters Locations
- ๐ Endosure - 2026 Funding Rounds & List of Investors - Tracxn
EMPLOYEESโ
FOUNDED2022
HQSparks Glencoe, MD, United States
Industry
Other Health Care
Tags
HealthTechDiagnostic EquipmentFemTechB2B
Investors
Not disclosed in the source filing. Form D filings do not list investors โ StreetZero surfaces them from news where available.
Key highlights
- Developed non-invasive 30-minute endometriosis diagnostic test with instant results
- Received NIH RADx Tech ACT ENDO Challenge award via partner 3CPM
- Angel-backed with headquarters in Sparks Glencoe, MD
- Focuses on women's health diagnostics gap
Ask StreetZero about EndoSure, Inc.
Put our AI to work on this deal.
Similar companies
Other Other Health Care deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account